Related Experiment Video
Updated: Nov 1, 2025
12:22
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.8K
[Biomarkers for renal cell tumours]
Philip Zeuschner1, Angela Zaccagnino1, Kerstin Junker1
1Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar.
Aktuelle Urologie
|June 22, 2021
Summary
Renal tumor subtyping has advanced significantly due to histopathological and molecular insights. Understanding these molecular alterations is key for developing targeted therapies and improving patient treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genitourinary Pathology
Background:
- Renal tumors show increasing differentiation based on histopathological and molecular features over the past 30 years.
- This improved classification impacts clinical practice for both organ-confined and metastatic renal cell tumors.
- Knowledge of molecular alterations is crucial for advancing therapeutic options.
Purpose of the Study:
- To provide an overview of the molecular differentiation of renal tumors.
- To discuss diagnostic, prognostic, and predictive biomarkers in renal cell carcinoma.
- To highlight the importance of molecular insights for targeted therapy development.
Main Methods:
- Review of recent histopathological and molecular classifications of renal tumors.
- Analysis of the literature on molecular alterations in renal cell carcinoma.
- Synthesis of information on biomarkers relevant to renal tumor management.
Main Results:
- Significant progress in subtyping renal tumors based on detailed molecular and histopathological analysis.
- Identification of key molecular drivers influencing tumor behavior and therapeutic response.
- Emergence of various biomarkers aiding in diagnosis, prognosis, and treatment selection.
Conclusions:
- Molecular subtyping is transforming the clinical management of renal tumors.
- Targeted therapies informed by molecular profiles offer improved outcomes for patients.
- Continued research into biomarkers is essential for personalized renal cancer treatment.
